Capricor Therapeutics faces renewed securities fraud lawsuit scrutiny as investors gain lead plaintiff opportunity
Executive summary: SBS Law issued a reminder on August 6, 2026, about a class action lawsuit against Capricor Therapeutics for alleged securities fraud, giving investors the opportunity to seek lead plaintiff status. The lawsuit stems from material disclosure concerns following FDA feedback on Capricor's Deramiocel therapy, which contributed to a 78.7% single-day stock drop and ongoing regulatory scrutiny.
Who is involved: Capricor Therapeutics (CAPR), Schall Brown & Schwartz LLP (SBS), investors who held CAPR stock during the class period, and the plaintiffs' legal team.
Likely next: Investors must move to appoint a lead plaintiff by the court deadline (expected September 28, 2026, based on related notices), after which discovery proceedings will likely intensify.
On August 6, 2026, Schall, Brown & Schwartz LLP reminded investors of an ongoing class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The notice highlights that investors who suffered losses have until a court-determined deadline to seek appointment as lead plaintiff. This follows prior disclosures in early August 2026 regarding FDA briefing documents that raised concerns about Deramiocel's efficacy, triggering a sharp stock decline and multiple investigations.
Timeline
- — Planet Fitness, Inc. Investor Alert: Contact SBS by September 14, 2026 for Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
- — GPGI, Inc. Investor Alert: Contact SBS by September 15, 2026 for Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (PR Newswire)
- — Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
- — Capricor (CAPR) Securities Investigation Notice - Levi & Korsinsky (PR Newswire)
Analysis — what this means
Likely next events
- Lead plaintiff motions due by September 28, 2026, per Levi & Korsinsky notice filed August 5, 2026
- Court to rule on lead plaintiff appointment likely Q4 2026
- Potential settlement discussions may begin post-discovery in early 2027
Sectors affected
- Biotechnology
- Regenerative medicine
- Cardiovascular therapeutics
Regulatory implications
- FDA may require additional clinical data for Deramiocel under accelerated approval pathways
Historical parallels
- Similar to Agenus Inc. (AGEN) 2021 lawsuit over failed cancer vaccine disclosures
- Parallels Editas Medicine (EDIT) 2020 securities claims following CRISPR trial setbacks
- Mirrors Fate Therapeutics (FATE) 2022 case involving iPSC therapy trial communication issues
Key entities
Sources
Open the full interactive case file on Beyond →